NICE approved payer reimbursement for Genmab’s tisotumab vedotin (Tivdak) for advanced recurrent or metastatic cervical cancer in updated draft-to-final guidance. NICE had previously rejected the ADC in March 2026 due to cost-effectiveness concerns. In its latest guidance draft, NICE cited uncertainty in economic modeling but said the company reached a confidential discount agreement with NHS England that mitigates the earlier concerns. NICE also noted that the ADC improved overall survival and progression-free survival compared with single-agent chemotherapy in the Phase 3 trial population. The April move matters for real-world access because payer decisions in England can determine whether patients receive ADC therapy after prior treatment lines. The decision follows MHRA authorization in December 2025, creating a second major regulatory step for Tivdak in Europe.